Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2015

View Archived Issues

Clinical evidence of the utility of a new drug delivery system for the treatment of autism

New device shows potential for monitoring patients under OAT

Uncovering a drug-targetable proinflammatory pathway associated with acute respiratory syndrome

Dipraglurant demonstrates efficacy in multiple preclinical models

Azapeptide analogue exerts cardioprotective effects

Genmab enters into license agreement with Novo Nordisk for DuoBody technology

Neurocrine completes enrollment in phase III trial of NBI-98854

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

Allergan describes formyl peptide modulators

Roche to acquire GeneWEAVE BioSciences

Bayer Schering Pharma patent details antimitotic agents

Neuropore Therapies divulges ASYN aggregation inhibitors

AbbVie reports TrK-A inhibitors

Funding supports Biogazelle's work on long non-coding RNAs in cancer

Proteon initiates second phase III study of vonapanitase

FDA approves IND for Saniona's NS-2359 in the treatment of cocaine addiction

AXIM conducting clinical trials of MedChew RX chewing gum in Europe

Merck & Co. discloses novel series of BACE1 inhibitors for AD

First patients randomized in phase IIa trial of SER-150 in diabetic nephropathy

CDC exercises contract options for Emergent's VIGIV program

Phase II BIRCH study of atezolizumab meets primary endpoint

Phase I/II study of INV-103 in systemic lupus erythematosus complete

Onconova Therapeutics submits IND for new phase III study of intravenous rigosertib

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...